A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers-Reference-Cited by-同舟云学术

A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers

Published:2017-03 Issue:3 Volume:144 Page:486-490
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Reiss Kim A.,Herman Joseph M.,Armstrong Deborah,Zahurak Marianna,Fyles Anthony,Brade Anthony,Milosevic Michael,Dawson Laura A.,Scardina Angela,Fischer Patricia,Hacker-Prietz Amy,Kinders Robert J.,Wang Lihua,Chen Alice,Temkin Sarah,Horiba Naomi,Stayner Lee-Anne,Siu Lillian L.,Azad Nilofer S.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference24 articles.

1. A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis;Reiss;Clin. Cancer Res.,2015

2. Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target;Chalmers;Clin. Oncol. (R. Coll. Radiol.),2004

3. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma;Tentori;FASEB J.,2006

4. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361;Calabrese;J. Natl. Cancer Inst.,2004

5. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor;Miknyoczki;Mol. Cancer Ther.,2003

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOPROGRESSIVE OVARIAN CANCER PATIENTS TREATED DURING PARP INHIBITOR MAINTENANCE: EFFICACY AND ADVERSE EVENTS FROM THE EPIMETHEO RETROSPECTIVE STUDY;International Journal of Radiation Oncology*Biology*Physics;2024-09

2. Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation‐Responsive Nanovesicles for Lung Cancer Chemoradiotherapy;Advanced Healthcare Materials;2024-04-21

3. PARP inhibitors combined with radiotherapy: are we ready?;Frontiers in Pharmacology;2023-10-26

4. Statistical methods and data visualisation of patient-reported outcomes in early phase dose-finding oncology trials: a methodological review;eClinicalMedicine;2023-10

5. Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer?;Healthcare;2023-08-28